There is an association between the rising generic drug prices and the changing levels of market competition, according to a study published in Annals of Internal Medicine.
There is an association between the rising generic drug prices and the changing levels of market competition, according to a study published in Annals of Internal Medicine.
Many patients utilize and rely on generic drugs for their medication needs, but rising prices make it more difficult to afford and maintain care. This retrospective study explored the causes for the continuous increase in generic drug prices by determining the influence of the market competition levels.
Data was collected from MarketScan Commercial Claims and Encounters, an employer and health plan drug database, from January 2008 to June 2013, as well as Red Book, a drug information database. The collected research from 5-and-a-half years was separated into 11 periods of 6 months. For each period, average drug prices were calculated to be compared to the baseline period (the first 6-month period). The market competition was then qualified using the Herfindahl-Hirschman Index (HHI), which quantifies market shares.
“The primary association of interest was between competition levels (HHI) and changes in drug prices,” wrote the authors. “Prices may increase faster for drugs with low baseline competition levels (time-stable component of HHI) or for those that become less competitive over time (time-varying component of HHI).”
Of the 1120 generic drugs included in the study period, there was an average price increase of 30%, while the weighted price (baseline market size was used at continuous variable) decreased by 14.2%. However, drugs in the group categorized as low-competition demonstrated a 63.8% increase in average price; there was a 43.8% increase for those in medium competition, and 9.7% increase among those in high competition.
The research found an association between lower or decreasing market competition levels and a rise in the generic drug prices.
“We found that increases in generic drug prices were strongly associated with market competition levels,” concluded the research. “Unless policies are enacted to stabilize generic drug markets in response to a decrease in competition, we may continue to see cases of generic drugs subject to large price increases.”
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More